Journal
EUROPEAN NEUROLOGY
Volume 62, Issue 1, Pages 1-8Publisher
KARGER
DOI: 10.1159/000215875
Keywords
Levodopa; Levodopa, historical perspective; Levodopa therapy, complications; Parkinson's disease; Dopa decarboxylase inhibition; Catechol-O-methyltransferase inhibition
Categories
Funding
- Novartis Pharmaceuticals Corp.
- Orion Pharma
- Valeant Pharmaceuticals
- Impax Laboratories
- Solvay Pharmaceuticals
Ask authors/readers for more resources
Levodopa has been the mainstay of treatment for Parkinson's disease (PD) for more than 40 years. During this time, researchers have strived to optimize levodopa formulations to minimize side effects, enhance central nervous system (CNS) bioavailability, and achieve stable therapeutic plasma levels. Current strategies include concomitant treatment with inhibitors of dopa decarboxylase (DDC) and catechol-O-methyltransferase (COMT) to prolong the peripheral levodopa half-life and increase CNS bioavailability. Levodopa combined with DDC inhibition is the current standard method of delivering levodopa for symptomatic treatment of PD. Recent research suggests that continuous dopaminergic stimulation that more closely approximates physiological stimulation may delay or prevent the development of motor fluctuations ('wearing off') and dyskinesias. Strategies currently being used to achieve more continuous dopaminergic stimulation include the combination of an oral levodopa/DDC inhibitor with a COMT inhibitor and the enteral infusion of a levodopa gel formulation. Attempts are underway to develop oral and transdermal very long-acting levodopa preparations. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available